Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

Phase 2

Recruiting

Conditions: Pancreatic Cancer
Radiotherapy

Interventions: Drug: mFOLFIRINOX plus IMRT

First Posted Date: 2024-02-08

Last Posted Date: 2024-05-09

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT06249321

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )

Recruiting

Conditions: Ovarian Cancer

Interventions: Other: Blood collection

First Posted Date: 2024-02-08

Last Posted Date: 2024-02-08

Lead Sponsor: Fudan University

Target Recruit Count: 168

Registration Number: NCT06249308

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China

WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases

Phase 1

Recruiting

Conditions: Brain Metastases
SCLC,Extensive Stage

Interventions: Radiation: HA-WBRT plus SBRT

First Posted Date: 2024-02-05

Last Posted Date: 2024-02-07

Lead Sponsor: Fudan University

Target Recruit Count: 56

Registration Number: NCT06243003

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China

Not Applicable

Recruiting

Conditions: HPV Vaccine

Interventions: Other: Vaccine chatbot that offering HPV vaccine-related information

First Posted Date: 2024-01-29

Last Posted Date: 2024-06-12

Lead Sponsor: Fudan University

Target Recruit Count: 1800

Registration Number: NCT06227689

Locations: 🇨🇳
Jiading District Center for Disease Control and Prevention, Shanghai, Shanghai, China
🇨🇳
Chizhou Health Center for Disease Control and Prevention, Chizhou, Anhui, China

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

Phase 4

Recruiting

Conditions: HER2-negative Breast Cancer
Leptomeningeal Metastasis

Interventions: Device: Ommaya reservoir
Drug: Systematic chemotherapy

First Posted Date: 2024-01-29

Last Posted Date: 2024-03-26

Lead Sponsor: Fudan University

Target Recruit Count: 48

Registration Number: NCT06230055

Locations: 🇨🇳
Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

Phase 2

Recruiting

Conditions: MALT Lymphoma of Stomach
Helicobacter Pylori Infection

Interventions: Drug: Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib
Drug: Triple therapy for eradication of Helicobacter Pylori

First Posted Date: 2024-01-29

Last Posted Date: 2024-02-23

Lead Sponsor: Fudan University

Target Recruit Count: 160

Registration Number: NCT06228963

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Recruiting

Conditions: Refractory Colorectal Carcinoma
Metastatic Colorectal Cancer
Colorectal Cancer

Interventions: Drug: Fruquintinib Combined With TAS-102

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06221423

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer
Microsatellite Stable Colorectal Carcinoma
RAS Mutation
Cadonilimab

Interventions: Drug: Cadonilimab + bevacizumab + FOLFOX

First Posted Date: 2024-01-23

Last Posted Date: 2024-01-23

Lead Sponsor: Fudan University

Target Recruit Count: 53

Registration Number: NCT06218810

Locations: 🇨🇳
Zhongshan hosptial, Fudan University, Shanghai, China

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Phase 3

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
Drug: gemcitabine; capecitabine

First Posted Date: 2024-01-22

Last Posted Date: 2024-01-22

Lead Sponsor: Fudan University

Target Recruit Count: 524

Registration Number: NCT06217042

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Phase 2

Not yet recruiting

Conditions: TNBC
Brain Metastasis

Interventions: Drug: SHR-A1921 + Bevacizumab

First Posted Date: 2024-01-18

Last Posted Date: 2024-01-18

Lead Sponsor: Fudan University

Target Recruit Count: 24

Registration Number: NCT06210438

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy